Kiora Pharmaceuticals INC: insider trades · United States · SEC (Form 4)

About Kiora Pharmaceuticals INC

Kiora Pharmaceuticals Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ under the ticker KPRX, and it is the issuer referenced in SEC Form 4 insider-transaction filings. Headquartered in Encinitas, California, United States, Kiora is focused on ophthalmology, with a development strategy centered on innovative therapies for serious retinal diseases. The company was incorporated in Delaware on December 28, 2004, giving it a long operating history in the biotech sector even though it remains a clinical-stage company rather than a commercial-stage pharmaceutical platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000047/kprx-20260331.htm?utm_source=openai)) Kiora operates as a single-segment specialty pharmaceutical company focused on ophthalmic products. Its pipeline is currently anchored by two lead programs. KIO-301 is being developed for inherited retinal diseases, especially retinitis pigmentosa, and is designed to target surviving retinal ganglion cells. KIO-104 is an anti-inflammatory candidate aimed at retinal inflammatory conditions, including retinal macular edema. These programs form the core of the company’s investment case. At present, Kiora does not have the diversified commercial portfolio or revenue base of a large-cap drugmaker; instead, it is largely dependent on clinical execution, regulatory progress, and capital access. ([kiorapharma.com](https://kiorapharma.com/technology/kio-301/?utm_source=openai)) From a competitive standpoint, Kiora is a niche player in a highly competitive ophthalmology market dominated by larger companies with greater clinical, regulatory, and commercial resources. Its differentiation lies in a focused approach to rare retinal disorders, where unmet medical need remains significant and where successful proof-of-concept data could create partnering or licensing opportunities. That same focus, however, also concentrates risk: the company’s valuation is highly sensitive to trial outcomes, regulatory milestones, and financing conditions. ([ir.kiorapharma.com](https://ir.kiorapharma.com/news-events/news-releases/detail/152/kiora-pharmaceuticals-receives-clinical-trial-approval-for-first-in-human-evaluation-of-kio-301-to-restore-vision-in-patients-with-retinitis-pigmentosa?utm_source=openai)) Recent corporate developments have been important. In March 2026, Kiora reported progress across two active Phase 2 studies, including ABACUS-2 for KIO-301 and KLARITY for KIO-104. In April 2026, the company announced an equity financing involving common stock and warrants, underscoring ongoing capital management in a development-stage model. Its March 31, 2026 quarterly filing stated that, based on cash and short-term investments plus April 2026 financing proceeds, Kiora expected to fund planned operations into late 2028. For investors, this leaves Kiora as a high-risk, high-upside ophthalmic biotech story on the NASDAQ in the United States, with value creation tied primarily to clinical and regulatory success. ([ir.kiorapharma.com](https://ir.kiorapharma.com/sec-filings/all-sec-filings/content/0001372514-26-000025/ex991-pressreleasedecember.htm?utm_source=openai))